AR058180A1 - Indeno derivados, su preparacion y su uso como medicamentos - Google Patents
Indeno derivados, su preparacion y su uso como medicamentosInfo
- Publication number
- AR058180A1 AR058180A1 ARP060104876A ARP060104876A AR058180A1 AR 058180 A1 AR058180 A1 AR 058180A1 AR P060104876 A ARP060104876 A AR P060104876A AR P060104876 A ARP060104876 A AR P060104876A AR 058180 A1 AR058180 A1 AR 058180A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- independently selected
- substituted
- phenyl
- radical
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/45—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by at least one doubly—bound oxygen atom, not being part of a —CHO group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
- C07C205/56—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups bound to carbon atoms of six-membered aromatic rings and carboxyl groups bound to acyclic carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
- C07C211/30—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system formed by two rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
- C07C225/22—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C233/11—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/78—Halides of sulfonic acids
- C07C309/86—Halides of sulfonic acids having halosulfonyl groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
- C07C311/44—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
- C07C311/46—Y being a hydrogen or a carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
- C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Abstract
La presente hace referencia a su procedimiento de preparacion, a su aplicacion como medicamento y a composiciones farmacéuticas que los comprenden. Los compuestos muestran afinidad por los receptores 5-HT6 por lo que se utilizan para el tratamiento de las enfermedades mediadas por estos receptores. Reivindicacion 1: Un indeno derivado de formula general (1) donde: n es 0, 1, 2, 3 o 4; R1 representa un radical cicloalifático saturado o insaturado, opcionalmente al menos monosustituido, opcionalmente al menos con un heteroátomo seleccionado entre N, O y S como miembro del anillo que puede estar condensado con un sistema anular mono o policíclico opcionalmente al menos monosustituido; un radical -NR8R9-; un radical -CONR8R9; -COOH; o -OH donde R8 y R9 representan, independientemente entre sí, un átomo de H; o un radical alifático C1-5 lineal o ramificado, saturado o insaturado, que puede estar sustituido con 1, 2, 3 sustituyentes seleccionados independientemente entre F, Cl, Br, -OH, -NH2, -SH, -O-CH3, -O-C2H5, -NO2, -CN, -NH-CH3 y -S-CH3; R8 y R9 conjuntamente con el N forman un anillo heterocíclico de 3 a 9 miembros saturado, insaturado o aromático, que puede estar sustituido con 1, 2 o 3 sustituyentes seleccionados independientemente entre C1-5 alquil, -O-C1-5 alquil, -S-C1-5-alquil, oxo (=O), tioxo (=S), -C(=O)-OH, -C(=O)-O-C1-5-alquil, -O-C(=O)-C1-5 alquil, F, Cl. Br, I, -CN, -CF3, -OCF3, -SCF3, -OH, -SH, -NH2, -NH(C1-5 alquil), -N(C1-5 alquil)2, -NO2, -CHO, -CF2H, -CFH2, -C(=O)-NH2, -C(=O)-NH(C1-5 alquil), -C(=O)-N(C1-5 alquil)2, -S(=O)2-C1-5 alquil, -S(=O)2-fenil y que pueden contener 1, 2 o 3 heteroátomos adicionales independientemente seleccionados entre N, O y S como miembros del anillo; R2, R3, R4 y R5 representan, independientemente entre sí, un átomo de H, -NO2, -NH2, -SH, -OH, -CN, -C(=O)-H, -C(=O)-R10, -OR11, -SR12, -SOR13, -S(=O)2-E13, S(=O)2-N(R14)R15, -N(R16)-S(=O)2-R17, -NH-R18, -NR19R20, -N(R21)-CO-R22; F, Cl, BR, I, un radical alifático C1-6 lineal o ramificado, saturado o insaturado, que puede estar sustituido por 1, 2 o 3 sustituyentes independientemente seleccionados entre F, Cl, Br, -OH, -NH2, -SH, -O-CH3, -O-C2H5, -NO2, -CN, -NH-CH3 y -S-CH3; o un radical arilo o heteroarilo de 5 a 14 miembros, que puede estar sustituido con 1, 2 o 3 sustituyentes independientemente seleccionados entre -CF3, C1-5- alquil, -O-C1-5- alquil, -S-C1-5-alquil, -C(=O)-OH, -C(=O)-O-C1-5 alquil, -O-C(=O)-C1-5-alquil, F, Cl Br, I, - CN, -OCF3, -SCF3, -OH, -SH, -NH2, -NH(C1-5 alquil), -N(C1-5 alquil)2, -NH-C(=O)-C1-5 alquil, -N(C1-5-alquil)-C(=O)-C1-5-alquil, -NO2, -CHO, -CF2H, -CFH2, -C(=O)-NH2, -C(=O)-NH(C1-5 alquil), -C(=O)-N(C1-5 alquil)2, -S(=O)2-C1-5 alquil, -S(=O)2-fenil, ciclopropil, ciclobutil, ciclopentil, ciclohexil, fenil, fenoxi, benciloxi y bencil y que pueden estar unidos a través de un grupo C1-6 alquileno lineal o ramificado y donde el radical heteroarilo contiene 1, 2 o 3 heteroátomos independientemente seleccionados entre N, O y S como miembros del anillo; con la condicion de que al menos uno de los sustituyentes R2, R3, R4 y R5 represente un radical -NO2, -SOR13, -S(=O)2-R13, -S(=O)2-N(R14)R15, -N(R16)-S(=O)2-R17, -N(R21)-CO-R22; A representa C=C(R6)R'6 o (R6)C-R'6 lo que significa, respectivamente, compuestos tipos (2) y (3); R6 y R'6, idénticos o diferentes, representan un átomo de H, -NO2, -NH2, -SH, -OH, -CN, -C(=O)-R10, -OR11, -SR12, F, Cl, BR, I, un radical alifático C1-10 lineal o ramificado, saturado o insaturado, que puede estar sustituido por 1, 2 o 3 sustituyentes independientemente seleccionados entre F, Cl, Br, -OH, -SH, -O-CH3, -O-C2H5, -NO2, -CN, y -S-CH3; o un radical arilo o heteroarilo de 5 a 14 miembros, que puede ser sustituido por 1, 2 o 3 sustituyentes independientemente seleccionado entre -CF3, C1-5- alquil, -O-C1-5- alquil, -S-C1-5-alquil, -C(=O)-OH, -C(=O)-O-C1-5 alquil, -O-C(=O)-C1-5-alquil, F, Cl Br, I, -CN, -OCF3, -SCF3, -OH, -SH, -NH2, -NH(C1-5 alquil), -N(C1-5 alquil)2, -NH-C(=O)-C1-5 alquil, -N(C1-5-alquil)-C(=O)-C1-5-alquil, -NO2, -CHO, -CF2H, -CFH2, -C(=O)-NH2, -C(=O)-NH(C1-5 alquil), -C(=O)-N(C1-5 alquil)2, -S(=O)2-C1-5 alquil, -S(=O)2-fenil, ciclopropil, ciclobutil, ciclopentil, ciclohexil, fenil, fenoxi, benciloxi y bencil y que pueden estar unidos a través de un grupo C1-6 alquileno, C2-6 alquenileno o C1-6 ilideno lineales o ramificados y donde el radical heteroaril contiene 1, 2 o 3 heteroátomos independientemente seleccionados entre N, O y S como miembros del anillo; R7 representa un átomo de H, un radical alifático C1-6 lineal o ramificado que pude estar sustituido por 1, 2 o 3 sustituyentes independientemente seleccionados entre F, Cl, Br, -OH, -SH, -O- CH3, -O-C2H5, -NO2, -CN y -S-CH3; R10 a R22 representan, independientemente entre sí, un átomo de H, un radical alifático C1-5 lineal o ramificado, saturado o insaturado, que puede estar sustituido con 1, 2 o 3 sustituyentes independientemente seleccionados entre F, Cl, Br, -OH, NH2, -SH, -O-CH3, -O-C2H5, -NO2, -CN, -NH-CH3 y -S-CH3; un radical cicloalifático de 3 a 8 miembros saturado o insaturado, que puede estar sustituido con 1, 2 o 3 sustituyentes seleccionados entre C1-5-alquil, -O- C1-5-alquil, -S-C1-5-alquil, oxo (=O), tioxo (=S), -C(=O)-OH, -C(=O)-O-C1-5 alquil, -O-C(=O)-C1-5 alquil, F, Cl, Br, I, -CN, -CF3, -OCF3, -SCF3, -OH, -SH, -NH2, -NH(C1-5 alquil), -N(C1-5 alquil)2, -NO2, -CHO, -CF2H, -CFH2, -C(=O)-NH2, -C(=O)NH(C1-5 alquil), -C(=O)-NC1-5 alquil)2, -S(=O)2-C1-5 alquil, -S(=O)2-fenil, ciclopropil, ciclobutil, ciclopentil, ciclohexil, fenil, fenoxi, benciloxi y bencil y que opcionalmente puede contener 1, 2 o 3 heteroátomos independientemente seleccionados entre N, O y S como miembros del anillo y que pueden estar unidos a través de un grupo C1-6 alquileno lineal o ramificado; o un radical arilo o heteroarilo de 5 a 14 miembros que puede estar sustituidos con 1, 2 o 3 sustituyentes independientemente seleccionados entre -CF3, C1-5- alquil, -O-C1-5- alquil, -S-C1-5-alquil, -C(=O)-OH, -C(=O)-O-C1-5 alquil, -O-C(=O)-C1-5-alquil, F, Cl Br, I, -CN, -OCF3, -SCF3, -OH, -SH, -NH2, -NH(C1-5 alquil), -N(C1-5 alquil)2, -NH-C(=O)-C1-5 alquil, -N(C1-5- alquil)-C(=O)-C1-5-alquil, -NO2, -CHO, -CF2H, -CFH2, -C(=O)-NH2, -C(=O)-NH(C1-5 alquil), -C(=O)-N(C1-5 alquil)2, -S(=O)2-C1-5 alquil, -S(=O)2-fenil, ciclopropil, ciclobutil, ciclopentil, ciclohexil, fenil, fenoxi, benciloxi y bencil y que pueden estar unidos a través de un grupo C1-6 alquileno, C2-6 alquenileno o C2-6 alquinileno lineales o ramificados y donde el radical heteroarilo contiene 1, 2 o 3 heteroátomos independientemente seleccionados entre N, O y S como miembros del anillo; con la condicion de que cuando R1 sea -COOH; R2, R3, R4 o R5 no sean -SOR13, -S(=O)2-R13 o -S(=O)2-N(R14)R15 y A no represente C=C(R6)R6' dándose la situacion conjunta en que R6 o R6' sean uno H y el otro un fenilo sustituido por -S(=O)2-C1-5 alquil, - NH2, -O-C1-5 alquil, F, Cl, Br, CN, -C(=O)-OH o -C(=O)-O-C1-5 alquil, o la situacion en que tanto R6 como R6' representen -OR11, y con la condicion de que cuando R1 sea -OH; R2, R3, R4 o R5 no sean -S(=O)2-R13 o -S(=O)2-N(R14)R15, y con la condicion de que cuando R1 sea -CONR8R9; R2, R3, R4 o R5 no sean -SOR13, -S(=O)2-R13 o -S(=O)2-N(R14)R15 y A no represente C=C(R6)R'6 dándose la situacion conjunta en que R6 o R'6 sean uno H y el otro un fenilo sustituido por -S(=O)2-C1-5 alquil, -NH2, -O-C1- 5 alquil, F, Cl, Br, CN, -C(=O)-OH o -C(=O)-O-C1-5 alquil, o una sal farmacéuticamente aceptable, un isomero, un profármaco o un solvato del mismo, opcionalmente en forma de uno de sus esteroisomeros, preferiblemente enantiomeros o diasteromeros, un racemato o en forma de una mezcla de al menos dos esteroisomeros, preferiblemente enantiomeros y/o diasteromeros, en cualquier proporcion de mezcla o una sal fisiologicamente aceptable de los mismos o el correspondiente solvato de los mismos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73504205P | 2005-11-08 | 2005-11-08 | |
ES200502720A ES2274725B1 (es) | 2005-11-08 | 2005-11-08 | Indeno derivados, su preparacion y su uso como medicamentos. |
Publications (1)
Publication Number | Publication Date |
---|---|
AR058180A1 true AR058180A1 (es) | 2008-01-23 |
Family
ID=37735250
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060104876A AR058180A1 (es) | 2005-11-08 | 2006-11-07 | Indeno derivados, su preparacion y su uso como medicamentos |
Country Status (7)
Country | Link |
---|---|
US (1) | US8217041B2 (es) |
EP (2) | EP2202222A3 (es) |
JP (1) | JP2009514915A (es) |
AR (1) | AR058180A1 (es) |
CA (1) | CA2628856A1 (es) |
TW (1) | TW200736189A (es) |
WO (1) | WO2007054257A2 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0715160A2 (pt) | 2006-08-08 | 2013-06-11 | Sanofi Aventis | imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso |
ES2358288T3 (es) | 2007-08-01 | 2011-05-09 | Laboratorios Del Dr. Esteve S.A. | Combinación de al menos dos ligandos de 5ht6. |
EP2053052A1 (en) | 2007-10-23 | 2009-04-29 | Laboratorios del Dr. Esteve S.A. | Process for the preparation of 6-substituted imidazo[2,1-b]thiazole-5-sulfonyl halide |
EP2236511A4 (en) | 2007-12-21 | 2011-04-13 | Alla Chem Llc | LIGANDS OF ALPHA ADRENOCEPTORS AND OF DOPAMINE, HISTAMIN, IMIDAZOLIN AND SEROTONIN RECEPTORS AND THEIR APPLICATION THEREOF |
EP2116547A1 (en) * | 2008-05-09 | 2009-11-11 | Laboratorios Del. Dr. Esteve, S.A. | Substituted N-imidazo(2, 1-b) thiazole-5-sulfonamide derivatives as 5-TH6 ligands |
EP2310372B1 (en) | 2008-07-09 | 2012-05-23 | Sanofi | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
BR112012003973A2 (pt) | 2009-08-26 | 2015-09-08 | Sanofi Sa | hidratos de fluoroglicosídeo heteroaromático cristalinos, produtos farmacêuticos compreendendo estes compostos e seu uso |
US8901114B2 (en) | 2011-03-08 | 2014-12-02 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8710050B2 (en) | 2011-03-08 | 2014-04-29 | Sanofi | Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
EP2683705B1 (de) | 2011-03-08 | 2015-04-22 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120053A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2682391A1 (en) | 2012-07-03 | 2014-01-08 | Laboratorios Del. Dr. Esteve, S.A. | Indene derivatives, their preparation and use as medicaments |
US9862698B2 (en) * | 2014-12-16 | 2018-01-09 | Adt Pharmaceuticals, Inc. | Indenyl compounds, pharmaceutical compositions, and medical uses thereof |
EP3784228A1 (en) | 2018-04-26 | 2021-03-03 | ADT Pharmaceuticals, LLC | Anticancer indenes, indanes, azaindenes, azaindanes, pharmaceutical compositions and uses |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3325358A (en) * | 1962-06-06 | 1967-06-13 | Merck & Co Inc | Method of treating inflammation |
US3622623A (en) * | 1968-08-28 | 1971-11-23 | Merck & Co Inc | 1-substituted indenyl-3-aliphatic acids and esters |
US3692325A (en) * | 1971-03-22 | 1972-09-19 | Joseph Mercadante | Air suspension with saddle members |
SE7700500L (sv) * | 1976-01-20 | 1977-07-21 | Hoechst Ag | Tiazolidinderivat och forfarande for deras framstellning |
JPS539752A (en) * | 1976-07-16 | 1978-01-28 | Sankyo Co Ltd | 4-substituted indanones |
DE3208079A1 (de) * | 1982-03-04 | 1983-09-08 | Schering AG, 1000 Berlin und 4709 Bergkamen | Neue indanyl-derivate, ihre herstellung und verwendung |
JPS6160610A (ja) * | 1984-08-31 | 1986-03-28 | Otsuka Pharmaceut Co Ltd | 低酸素症改善剤 |
GB8628644D0 (en) * | 1986-12-01 | 1987-01-07 | Lunbeck A S H | Intermediates |
PT89205B (pt) | 1987-12-14 | 1993-06-30 | Beecham Group Plc | Processo para a preparacao de derivados de indano |
US5092827A (en) | 1989-09-28 | 1992-03-03 | International Paper Box Machine Co., Inc. | Apparatus for folding paper boxes |
GB9414139D0 (en) | 1994-07-13 | 1994-08-31 | Smithkline Beecham Plc | Novel compounds |
US5776962A (en) * | 1994-08-03 | 1998-07-07 | Cell Pathways, Inc. | Lactone compounds for treating patient with precancerous lesions |
GB9420521D0 (en) | 1994-10-12 | 1994-11-30 | Smithkline Beecham Plc | Novel compounds |
AU699727B2 (en) | 1995-02-02 | 1998-12-10 | Smithkline Beecham Plc | Indole derivatives as 5-HT receptor antagonist |
GB9517559D0 (en) | 1995-08-26 | 1995-10-25 | Smithkline Beecham Plc | Novel compounds |
US5965619A (en) * | 1996-06-13 | 1999-10-12 | Cell Pathways Inc. | Method for treating patients having precancerous lesions with substituted indene derivatives |
US6028116A (en) * | 1998-04-03 | 2000-02-22 | Cell Pathways, Inc. | Substituted condensation products of 1H-indenyl-hydroxyalkanes with aldehydes for neoplasia |
US5958982A (en) | 1998-04-17 | 1999-09-28 | Cell Pathways, Inc. | Method for treating patients with sarcoidosis by administering substituted sulfonyl indenyl acetic acids, esters and alcohols |
US20010006965A1 (en) | 1998-04-17 | 2001-07-05 | Rifat Pamukcu | Method for treating patients with diabetic retinopathy by administering substituted sulfonyl indenyl acetic acids and alcohols |
US20010020020A1 (en) * | 1998-04-17 | 2001-09-06 | Rifat Pamukcu | Method for treating patients with macular degeneration by administering substituted sulfonyl indenyl acetic acids and alcohols |
DE19831878C2 (de) * | 1998-07-17 | 2001-05-17 | Aventis Pharma Gmbh | Polycyclische Thiazolidin-2-yliden Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
US20030073850A1 (en) * | 1998-08-07 | 2003-04-17 | Altenbach Robert J. | 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use |
US6025394A (en) | 1999-01-29 | 2000-02-15 | Cell Pathways, Inc. | Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols |
AU2696502A (en) * | 2000-11-27 | 2002-06-03 | Merck & Co Inc | Estrogen receptor modulators |
ES2294342T3 (es) | 2002-11-22 | 2008-04-01 | Eli Lilly And Company | Benzoilsulfamidas antitumorales. |
EP1680447A2 (en) * | 2003-10-24 | 2006-07-19 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Orthogonal gene switches |
-
2006
- 2006-11-07 EP EP10155635A patent/EP2202222A3/en not_active Withdrawn
- 2006-11-07 JP JP2008539319A patent/JP2009514915A/ja active Pending
- 2006-11-07 EP EP06818389A patent/EP1960343B1/en not_active Not-in-force
- 2006-11-07 CA CA002628856A patent/CA2628856A1/en not_active Abandoned
- 2006-11-07 US US12/093,100 patent/US8217041B2/en not_active Expired - Fee Related
- 2006-11-07 WO PCT/EP2006/010627 patent/WO2007054257A2/en active Application Filing
- 2006-11-07 AR ARP060104876A patent/AR058180A1/es not_active Application Discontinuation
- 2006-11-08 TW TW095141243A patent/TW200736189A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
JP2009514915A (ja) | 2009-04-09 |
WO2007054257A2 (en) | 2007-05-18 |
US8217041B2 (en) | 2012-07-10 |
EP1960343A2 (en) | 2008-08-27 |
EP1960343B1 (en) | 2012-04-04 |
EP2202222A2 (en) | 2010-06-30 |
WO2007054257A3 (en) | 2007-10-18 |
US20090163547A1 (en) | 2009-06-25 |
TW200736189A (en) | 2007-10-01 |
EP2202222A3 (en) | 2010-09-15 |
CA2628856A1 (en) | 2007-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR058180A1 (es) | Indeno derivados, su preparacion y su uso como medicamentos | |
AR069490A1 (es) | Agonistas de los receptores de glucocorticoides | |
AR054129A1 (es) | Derivados de 2, 6-quinolinilo, una preparacion farmaceutica que los contiene y su empleo en la fabricacion de medicamentos para el tratamiento de enfermedades dependientes de integrinas alfa4beta1 y/o alfa4beta7 | |
CL2021001396A1 (es) | Derivados de panteteína y usos de los mismos | |
AR034556A1 (es) | Un derivado de fenilalanina, una composicion farmaceutica que comprende al derivado de fenilalanina, el uso del derivado y proceso para preparar dicho derivado | |
AR051780A1 (es) | Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos | |
UY29393A1 (es) | Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones. | |
AR052938A1 (es) | Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por el receptor vr1 | |
BR0307409A (pt) | Compostos de hidrazida de ácido 2-furanocarboxìlico, composições farmacêuticas contendo os mesmos e uso dos mesmos para preparação de um agente preventivo ou terapêutico | |
BRPI0519287A2 (pt) | derivados de amida | |
CO6260076A2 (es) | Derivados de uracilo o timina para el tratamiento de la hepatitis c | |
AR060545A1 (es) | Compuestos de benzoaxol y benzotiazol 6-0- sustituidos y metodos de inhibicion de la senalizacion de csf-1r. composiciones farmaceuticas | |
AR041566A1 (es) | Derivados de indol utiles para el tratamiento de enfermedades | |
AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
AR052866A1 (es) | Fenil-metanonas monociclicas sustituidas | |
AR056886A1 (es) | Compuestos de pirrolopiridina sustituida inhibidores de quinasas, composiciones farmaceuticas que los contienen y usos en el tratamiento del cancer | |
UY29312A1 (es) | Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones | |
AR041260A1 (es) | Piperazinas sustituidas por heterociclos para el tratamiento de la esquizofrenia | |
PE20060689A1 (es) | Derivados de sulfonamidas como antagonistas de receptores orexina 2 | |
AR070810A1 (es) | Derivados de 1- bencil-3-hidroximetilindazol y su utilizacion en el tratamiento de enfermedades basadas en la expresion de mcp-1 cx3cr1 y p40 | |
ATE420859T1 (de) | Azabicycloä3.1.0ühexylphenylderivate als modulatoren von dopamin-d3-rezeptoren | |
AR068045A1 (es) | Derivados de catecolamina y prodrogas de los mismos | |
BRPI0907122B8 (pt) | compostos de piridoindóis (1-azinona) substituídos, composição farmacêutica compreendendo os referidos compostos, e usos dos mesmos | |
AR105522A1 (es) | Derivados de amida sustituida que tienen actividad multimodal contra el dolor | |
AR067454A1 (es) | Derivados de indano- amina, su preparacion y uso como medicamentos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |